All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. Multi criteria decision analysis to select priority diseases for Newborn blood screening

    KCE Reports 267 (2016)

    https://kce.fgov.be/en/multi-criteria-decision-analysis-to-select-priority-diseases-for-newborn-blood-screening

  2. The role of biomarkers in ruling out cerebral lesions in mild cranial trauma

    KCE Reports 261 (2016)

    https://kce.fgov.be/en/the-role-of-biomarkers-in-ruling-out-cerebral-lesions-in-mild-cranial-trauma

  3. Reduction of the treatment gap for problematic alcohol use in Belgium

    KCE Reports 258 (2016)

    https://kce.fgov.be/en/reduction-of-the-treatment-gap-for-problematic-alcohol-use-in-belgium

  4. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2

    KCE Reports 243 (2015)

    https://kce.fgov.be/en/oncogenetic-testing-diagnosis-and-follow-up-in-birt-hogg-dub%C3%A9-syndrome-familial-atypical-multiple

  5. Oncogenetic testing for persons with hereditary endocrine cancer syndromes

    KCE Reports 242 (2015)

    https://kce.fgov.be/en/oncogenetic-testing-for-persons-with-hereditary-endocrine-cancer-syndromes

  6. Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology

    KCE Reports 240 (2015)

    https://kce.fgov.be/en/next-generation-sequencing-gene-panels-for-targeted-therapy-in-oncology-and-haemato-oncology

  7. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening

    KCE Reports 238 (2015)

    https://kce.fgov.be/en/cervical-cancer-screening-program-and-human-papillomavirus-hpv-testing-part-ii-update-on-hpv-primary

  8. Gene expression profiling and immunohistochemistry tests for personalised management of adjuvant chemotherapy decisions in early breast cancer – a Rapid Assessment

    KCE Reports 237 (2015)

    https://kce.fgov.be/en/gene-expression-profiling-and-immunohistochemistry-tests-for-personalised-management-of-adjuvant

  9. Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li Fraumeni syndrome and Cowden syndrome

    KCE Reports 236 (2015)

    https://kce.fgov.be/en/oncogenetic-testing-and-follow-up-for-women-with-familial-breastovarian-cancer-li-fraumeni-syndrome

  10. The non-invasive prenatal test (NIPT) for trisomy 21 – health economic aspects

    KCE Reports 222 (2014)

    https://kce.fgov.be/en/the-non-invasive-prenatal-test-nipt-for-trisomy-21-%E2%80%93-health-economic-aspects

  11. Oncogenetic testing for Lynch syndrome and familial adenomatous polyposis

    KCE Reports 220 (2014)

    https://kce.fgov.be/en/oncogenetic-testing-for-lynch-syndrome-and-familial-adenomatous-polyposis

  12. Novel serum biomarkers for the prediction of cardiovascular risk

    KCE Reports 201 (2013)

    https://kce.fgov.be/en/novel-serum-biomarkers-for-the-prediction-of-cardiovascular-risk

  13. Manual for cost-based pricing of hospital interventions

    KCE Reports 178 (2012)

    https://kce.fgov.be/en/manual-for-cost-based-pricing-of-hospital-interventions

  14. [Is neonatal screening for cystic fibrosis recommended in Belgium?]

    KCE Reports 132 (2010)

    https://kce.fgov.be/en/is-neonatal-screening-for-cystic-fibrosis-recommended-in-belgium

  15. [Evaluation of universal and targeted hepatitis A vaccination programs in Belgium]

    KCE Reports 98 (2008)

    https://kce.fgov.be/en/evaluation-of-universal-and-targeted-hepatitis-a-vaccination-programs-in-belgium

  16. Nosocomial Infections in Belgium, part 1: national prevalence study

    KCE Reports 92 (2008)

    https://kce.fgov.be/en/nosocomial-infections-in-belgium-part-1-national-prevalence-study

  17. Laboratory tests in general practice

    KCE Reports 59 (2007)

    https://kce.fgov.be/en/laboratory-tests-in-general-practice

  18. Cervical Cancer Screening and Human Papillomavirus (HPV) Testing

    KCE Reports 38 (2006) 2nd print (1st print, September 2006)

    https://kce.fgov.be/en/cervical-cancer-screening-and-human-papillomavirus-hpv-testing

  19. [Molecular Diagnostics in Belgium]

    KCE Reports 20 (2005)

    https://kce.fgov.be/en/molecular-diagnostics-in-belgium

  20. [Preoperative risk assessment]

    KCE Reports 5 (2004) The routine peri-operative use of beta-blockers is no longer recommended In the KCE guidelines on pre-surgical examinations (KCE Reports 5-2004), the peri-operative use of beta-blockers (see page 10) was elaborately discussed. These recommendations were largely based on primary studies  To this date (February 2014), it appears that most of these studies are fraudulent. KCE therefore questions the peri-operative  administration of these agents. For more information: http://www.escardio.org/about/press/press-releases/pr-13/Pages/joint-statement-per

    https://kce.fgov.be/en/preoperative-risk-assessment

Pages